tlooto
Sign up
Medicine

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

C. Frey

2026.6.19INVESTIGATIONAL NEW DRUGS

DOI: 10.1007/s10637-026-01628-w

Abstract

Abstract is not available.

Citation format

FREY, C. Characterizing the post-market safety profile of cemiplimab: A pharmacovigilance study of the FDA adverse events reporting system database. INVESTIGATIONAL NEW DRUGS, 2026.